Buy Generic Tamoxifen 20mg

Nolvadex cheap analog from India, Best Prices, Guarantee Shipping

Active substance: Tamoxifen
U.S. Brand: Nolvadex
Indian Brand: Cytotam
Made by:
Strength: 20mg
Form release: blister with 10 tablets
Shipping time: 7 – 21 days
Best price: 0.35 USD
through request form

DescriptionHow to take?Common Side EffectsLatest New'sPhoto's

Tamoxifen in bodybuilding

Tamoxifen is classed as a specific estrogen receptor modulator or SERM. It acts as an estrogen antagonist in the brain and the breast area meaning it prevents estrogen from exerting its normal effect in those areas. With respect to its action in the brain it inhibits the conversion of testosterone to estrogen which during a cycle can mean that estrogen levels remain low. Although low estrogen is often considered advantageous by bodybuilders it should be noted that estrogen helps both with the accrual of muscle mass and also helps to boost libido on cycle. In fact, when bodybuilders use testosterone enhancing compounds and run tamoxifen alongside it, they often lose out on some of the muscle gains and enhanced libido that normally accompanies testosterone elevation.

For more than 30 years, bodybuilders have taken tamoxifen to prevent and treat gynaecomastia caused by use of anabolic steroids.

Tamoxifen mechanism of action

Tamoxifen is a nonsteroidal triphenylethylene derivative that binds to the estrogen receptor. Generic Nolvadex can be ordering through make request page. The mechanism of action of generic tamoxifen is complex. Clearly, its principal mechanism of action is mediated by its binding to the estrogen receptor and the blocking of the proliferative actions of estrogen on mammary epithelium.

Tamoxifen cost

The cost for tamoxifen oral tablet 20 mg is around $35 from India for a supply of 100 tablets, depending on the pharmacy. We offer additional discount 10% if you will leave a review about our services.

Tamoxifen Citrate Uses

Tamoxifen is used to treat breast cancer that has spread to other parts of the body (metastatic breast cancer), to treat breast cancer in certain patients after surgery and radiation therapy, and to reduce the chances of breast cancer in high-risk patients. We ship tamoxifen from India, for ordering instruction please use contact page.

Generic Novadex Tamoxifen used to treat cancer are very strong and can have many side effects. Before using this medicine, make sure you understand all the risks and benefits. It is important for you to work closely with your doctor during your treatment.

Swallow the tablets whole with a glass of water. Do not break, divide, crush, or chew it. You can take the tablets with or without food.

Tamoxifen sometimes causes mild nausea and vomiting. However, it may have to be taken for several weeks or months to be effective. Even if you begin to feel ill, do not stop using this medicine without first checking with your doctor. Ask your health care professional for ways to lessen these effects.

For oral dosage form (solution, tablets):

  • For breast cancer:
    • Adults—20 to 40 milligrams (mg) per day. Doses greater than 20 mg are given as 2 divided doses (morning and evening).
    • Children—Use and dose must be determined by your doctor.
  • For breast cancer as additional treatment:
    • Adults—20 milligrams (mg) per day for 5 to 10 years.
    • Children—Use and dose must be determined by your doctor.
  • For reducing the risk of developing breast cancer in high-risk women:
    • Adults—20 milligrams (mg) per day for 5 years.
    • Children—Use and dose must be determined by your doctor.
  • For reducing the risk of developing invasive breast cancer in women with ductal carcinoma in situ:
    • Adults—20 milligrams (mg) per day for 5 years.
    • Children—Use and dose must be determined by your doctor.

Store the Tamoxifen in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

The most common side effects of tamoxifen are: increased tumor or bone painhot flashesnausea.

Low-Dose Tamoxifen Feasible Option in Breast Cancer

Women appear to prevent recurrence in early stage cancers with 5 mg dosing

Amino Acid Leucine Found In Meat May Fuel Resistance To Breast Cancer Treatment Tamoxifen

Breast cancer patients who are resistant to the drug tamoxifen have poor health outcomes, but reducing meat protein in the diet could offer better results.

Tamoxifen is the standard treatment for estrogen-receptor-positive breast cancer. Many tumors became resistant to this endocrine drug that treating breast cancer becomes more difficult due to limited treatment options.

A group of researchers from the Cancer Center Institute at Beth Israel Deaconess Medical Center, a Harvard Medical School Teaching Hospital, discovered the relationship between levels of amino acid leucine and tamoxifen resistance.

Role Of Amino Acid Leucine

Leucine is one of the 20 types of amino acid that is not naturally produced in the body. Its common sources are beef, chicken, pork, and fish.

Lead author Senthil Muthuswamy, director of the cell biology program and deputy director of translational research in the Cancer Center Institute at BIDMC, said reducing the levels of amino acid leucine could potentially suppress tamoxifen resistance in ER-positive breast cancer patients.

“Our findings in the lab demonstrate that decreasing leucine levels suppresses proliferation of tumor cells, whereas increasing leucine enhances it. Furthermore, the findings open up the possibility that a low-leucine diet could be beneficial for patients with ER+ breast cancer,” Muthuswamy said.

Researchers manipulated the levels of leucine in cultured cells and found that a tenfold increase in the amino acid enhanced the ER-positive breast cancer cells’ division.

Further investigation also showed that cancer cells that grew to become resistant to tamoxifen were able to grow even with decreased leucine levels.

Decreasing the amount of leucine in the diet can improve the patients’ metabolic functions and overall health outcomes. Low-leucine, protein-rich plant-based diet will provide daily nutrients to ER-positive breast cancer patients.

Benefits Of Anti-Estrogen Drug

The addition of an anti-estrogen drug to the first-line treatment for ER-positive breast cancer is found beneficial to women who were initially exposed to endocrine therapy.

Dr. Rita Mehta, clinical professor at University of California Irvine, said fulvestrant can limit the supply of estrogen to the tumor. Low levels of estrogen reduces the growth of the cancer cells and delays the resistance to the drug anastrozole.

“The addition of fulvestrant to anastrozole was associated with increased long-term survival as compared with anastrozole alone, despite substantial crossover to fulvestrant after progression during therapy with anastrozole alone,”

recently published in The New England Journal of Medicine.

Researchers Uncover New Role for Tamoxifen in Triple-Negative Breast Cancers

Newswise — BUFFALO, N.Y. — One of the mechanisms that makes so-called triple-negative breast cancer (TNBC) notoriously aggressive and hard to treat is its ability to disarm proteins that suppress tumors and mutate them into tumor drivers. Seeking to better understand this process, a team from Roswell Park Comprehensive Cancer Center decided to focus not on what these TNBC tumors lack — the estrogen receptor (ER-alpha), progesterone receptor (PR), and HER2 proteins — but something they possess: an alternate estrogen receptor, ER-beta. What they found, in collaboration with an international team of researchers, and report in a new article in JNCI: Journal of the National Cancer Institute, is that a widely used breast cancer drug, tamoxifen, can turn the ER-beta protein into a double agent capable of disrupting the processes that typically make TNBC tumors so devastating.

Tamoxifen is approved for treatment and prevention of ER-alpha-positive breast cancers, but was previously thought not to be effective against TNBC tumors because it targets ER-alpha, one of the proteins they lack. But this new work from a team led by Gokul Das, PhD, Associate Professor of Oncology in the Department of Pharmacology and Therapeutics and Co-Director of the Breast Disease Site Research Group at Roswell Park, proposes a new role for this broadly studied and well-tolerated targeted agent: targeting ER-beta.

Mutation of an important tumor suppressor, the TP53 protein (also known as p53), is known to be the major mechanism behind most triple-negative breast tumors. In TNBC with normal TP53, ER-beta binds to normal TP53, disabling its tumor-suppressing capabilities and resulting in aggressive tumor behavior. But Dr. Das and colleagues show here that in TNBC with mutated TP53, ER-beta functions as a tumor suppressor by binding to mutated TP53, preventing it from functioning as a tumor driver.

“We demonstrate that ER-beta directly binds to TP53 and influences its function, and that what happens from there hinges on what type of TP53 the tumor cells have. ER-beta can have diametrically opposite functional capabilities depending on what type of TP53 — normal or mutated — is present in the tumors,” notes co-first author Chetan Oturkar, PhD, a research affiliate in Dr. Das’ lab.

The researchers report based on a series of preclinical studies that tamoxifen increases binding of ER-beta to mutated TP53 in TNBC leading to death of cancer cells, and their analysis of a large breast cancer patient database showed that high levels of ER-beta in TNBC with mutated TP53 are associated with a more favorable prognosis.

“We have uncovered what we believe is the first known prognostic marker for triple-negative breast cancer, opening up an important opportunity to repurpose tamoxifen to treat TNBC,” says Dr. Das. “We are particularly pleased and excited to see that a readily available drug that has safely been given to hundreds of thousands of patients with or at risk for other types of breast cancer may be used to treat a disease subtype for which there are no effective therapies at present.”


Submit your review

Create your own review

Average rating:  
 0 reviews